Results 81 to 90 of about 19,563 (105)

Mechanisms, Significance, Detection and Emerging Therapies for Carbapenem‐Resistant Enterobacterales: A Scoping Review

open access: yesJournal of Tropical Medicine, Volume 2026, Issue 1, 2026.
Background Carbapenems are among the most important broad‐spectrum β‐lactam antibiotics for the treatment of severe infections caused by multi–drug‐resistant Gram‐negative bacteria. However, the global emergence and dissemination of carbapenem‐resistant Enterobacterales (CRE), particularly carbapenemase‐producing Enterobacterales (CPE), have ...
Oluchi Judith Osuala   +8 more
wiley   +1 more source

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

open access: yesBMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader   +3 more
doaj   +1 more source

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model

open access: yes, 2018
The objective of these studies was to evaluate the exposures of meropenem and vaborbactam that would produce antibacterial activity and prevent resistance development in carbapenem-resistant Klebsiella pneumoniae carbapenemase ...
Debora Rubio-Aparicio   +7 more
core   +1 more source

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

open access: yesAntibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

open access: yes, 2017
We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistance phenotypes and carbapenemase genotypes.
Mariana Castanheira   +3 more
core   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

open access: yesBMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader   +4 more
doaj   +1 more source

Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China

open access: yesBMC Microbiology
Purpose This nine-year (2016–2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on ...
Yungang Han   +12 more
doaj   +1 more source

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

open access: yesJournal of Global Antimicrobial Resistance
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj   +1 more source

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents

open access: yesFrontiers in Microbiology
The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment ...
Emily Salisbury   +13 more
doaj   +1 more source

Multicenter clinical evaluation of Etest meropenem-vaborbactam (bioMérieux) for susceptibility testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa [PDF]

open access: yes, 2019
Meropenem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults.
Davies, Leanne   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy